Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs aflibercept ophthalmic Phase 2/3 trial in Japan
jRCT2080224581Phase 3Completed
- Start
- Mar 2019
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab in well-being (2 arms). Started Mar 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
well-being
Beyond the preview
Go deeper on jRCT2080224581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224581.